Synthetic Cell-Based Immunotherapies for Neurologic Diseases

The therapeutic success and widespread approval of genetically engineered T cells for a variety of hematologic malignancies spurred the development of synthetic cell-based immunotherapies for CNS lymphoma, primary brain tumors, and a growing spectrum of nononcologic disease conditions of the nervous...

Descripción completa

Detalles Bibliográficos
Autores principales: von Baumgarten, Louisa, Stauss, Hans J., Lünemann, Jan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474853/
https://www.ncbi.nlm.nih.gov/pubmed/37385738
http://dx.doi.org/10.1212/NXI.0000000000200139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474853/
https://www.ncbi.nlm.nih.gov/pubmed/37385738
http://dx.doi.org/10.1212/NXI.0000000000200139

Ejemplares similares